Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Non-Current Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Other Non-Current Assets for 4 consecutive years, with $230000.0 as the latest value for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 90.08% year-over-year to $230000.0; the TTM value through Dec 2025 reached $230000.0, up 90.08%, while the annual FY2025 figure was $230000.0, 90.08% up from the prior year.
  • Other Non-Current Assets was $230000.0 for Q4 2025 at Day One Biopharmaceuticals, down from $317000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $487000.0 in Q1 2023, with the low at $117000.0 in Q2 2024.
  • Historically, Other Non-Current Assets has averaged $264187.5 across 4 years, with a median of $222500.0 in 2025.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 195.15% in 2023 before it plummeted 65.71% in 2024.
  • Over 4 years, Other Non-Current Assets stood at $469000.0 in 2022, then crashed by 54.37% to $214000.0 in 2023, then tumbled by 43.46% to $121000.0 in 2024, then skyrocketed by 90.08% to $230000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $230000.0 in Q4 2025, $317000.0 in Q3 2025, and $183000.0 in Q2 2025.